Vivek Kohar

Vivek Kohar serves as Chief Technology Officer at Ampersand Biomedicines. Ampersand Biomedicines operates in the research sector with approximately 55.0 employees. Ampersand Biomedicines generates annual revenue of 1000000.0. To date, Ampersand Biomedicines has raised 115000000.0 in total funding, with the most recent round being Series B.

Industry & Role Insights

• • MessageCEO tracks 2,961 executives in the research sector.
• • We have verified contacts for 2 executives at Ampersand Biomedicines.
• • Our database includes 201,467 c suite-level executives.

Mimecast Outlook Microsoft Office 365 Amazon AWS Webflow Greenhouse.io Google Tag Manager Google Font API Mobile Friendly Vimeo Hotjar Typekit AI

biotechnology research programmable medicines precision therapeutics and platform biologics disease targeting localization modular medicines address map therapeutic effect cell targeting tissue selectivity safety effectiveness actuator moieties localizing elements multi-specific medicines drug localization biotechnology drug development clinical trials biopharmaceuticals healthcare innovation target engagement on-target therapy off-tissue side effects toxicology immunology drug discovery pharmaceutical technology r&d biomedical engineering therapeutic delivery biotech startup risk reduction treatment efficacy human health biocompatibility translational medicine personalized medicine multi-omics computational biology high-throughput screening ai in drug design antibody development clinical advancement therapeutic pipelines strategic partnerships investment in biotech healthcare solutions biomedical research health care health wellness & fitness hospital & health care research & development

JG

Jason Gardner CEO at Ampersand Biomedicines

SN

Srikanth Nandiraju Chief Technology Officer at 1Cell.Ai Inc.

SD

Surinnder Dang Chief Business Officer at 1Cell.Ai Inc.

M

Mark Chief Executive Officer at 23Strands

IT

Ilia Tikhomirov Chief Executive Officer at 35Pharma

Outreach Guidance — research Sector

Executives like Vivek Kohar in the research sector receive targeted outreach from sales teams, recruiters, and investors. To stand out, personalize your message with industry-specific context and a clear, specific value proposition relevant to their role at Ampersand Biomedicines.

Vivek Kohar's Position in the MessageCEO Database

• •Vivek Kohar is 1 of 2 verified executive contacts we track at Ampersand Biomedicines.
• •2,871 verified executive contacts in research are in the MessageCEO database.
• •30 verified contacts work at research companies in the 55.0 employee range (same size as Ampersand Biomedicines).

Executive contact data compiled from public business filings, LinkedIn public profiles, company press materials, and verified outbound email testing. We do not publish personal addresses or sensitive identifiers. Methodology & sources · Removal requests handled at /remove-info · Updated August 2026.

How do I reach Vivek Kohar directly?

Vivek Kohar's verified email address is available to MessageCEO Pro subscribers. They currently serve as Chief Technology Officer at Ampersand Biomedicines. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does Vivek Kohar work for?

Vivek Kohar is Chief Technology Officer at Ampersand Biomedicines, a company in the research sector with 55.0 employees.

Can I pitch or sell to Vivek Kohar?

As Chief Technology Officer at Ampersand Biomedicines, Vivek Kohar is a key decision-maker in the research sector. MessageCEO Pro gives you verified email to reach Vivek Kohar directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is Vivek Kohar in?

Vivek Kohar works in the research industry as Chief Technology Officer at Ampersand Biomedicines. MessageCEO provides verified contact information for executives across all major industries.

Is Vivek Kohar's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. Vivek Kohar's profile is kept up-to-date with the latest available information.

Last updated: August 29, 2026